The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Well someone just bought 200k with no trouble, so there must be stock around.
Just no one’s that keen to pay more than the current 60p or so.
Looks like we have about 100m shares ready to be sold if good news lands (can’t believe they’re long term investors).
Anyone else find it a bit weird that even the 100m or so shares in ‘public hands’ aren’t being traded?
Assuming this goes down to the wire, then the co. will issue an RNS as soon as they know the outcome of the FDA review.
So, on Friday Sept 30th (or the next business day, Mon 3rd Oct) can we assume a lot of shares will change hands?
Btw, if the co. issue an RNS on Fri or Mon, when will the actual FDA meeting/ decision have been made? And how can they keep it quiet?
Rarely does the day’s traded volumes exceed 0.5% of shares in issue. The major shareholders have supported the co. through the CRL episode - one suggesting that the FDA were simply ‘buying time’ as they were overloaded with Covid applications.
Fingers crossed that they’ve sorted themselves out this time.
Presumably as long as the company answers their questions satisfactorily then all should be well.
What’s the alternative?
‘We have heard nothing from the FDA’….
Non-approval yet again would be the height of incompetence, imho.